db-1303
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Jan 31, 2022 (NCT05150691)
Timeline
Indications
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06340568 | Phase 3 | Nov 30, 2024 | Biontech, DualityBio Inc. |
| NCT06018337 | Phase 3 | Jan 31, 2024 | DualityBio Inc. |
| NCT06265428 | Phase 3 | Jan 29, 2024 | Biontech, DualityBio Inc. |
| NCT05150691 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2022 | DualityBio Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| DualityBio Inc. | For profit | 4 | 3 | 2 | 2022 |
| Biontech | For profit | 2 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1